Famotidine

CLINICAL USE

H2-blocker:Conditions associated with hyperacidity

DOSE IN NORMAL RENAL FUNCTION

20–80 mg dailyZollinger-Ellison syndrome: 80–800 mg daily in divided doses

PHARMACOKINETICS

Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :337.4

%Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :15–20

%Excreted unchanged in urine &nbsp &nbsp : 25–30

Volume of distribution (L/kg) &nbsp &nbsp &nbsp :1.1–1.4

half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :3/>20

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 &nbsp &nbsp : Dose as in normal renal function

10 to 20 &nbsp &nbsp : 50% of normal dose

<10 &nbsp &nbsp &nbsp &nbsp &nbsp : 20 mg at night (maximum)

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL/min

HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL/min

HDF/high flux &nbsp :Not dialysed. Dose as in GFR <10 mL/min

CAV/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR=10–20 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

Antifungals: absorption of itraconazole and ketoconazole reduced

Ciclosporin: possibly increased ciclosporin levelsCytotoxics: possibly reduced dasatinib concentration

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

Tags: post-by-auto-php